⏱ News is delayed by 15 minutes. Sign in for real-time access.
Sign in
WHWK News
Whitehawk Therapeutics, Inc. Common Stock
Whitehawk Therapeutics Presents Real‑World Analysis Confirming SEZ6 as a Highly Expressed, Clinically Relevant Target for SCLC and Other Neuroendocrine Tumors at ASCO 2026
prnewswire.com
WHWK
Form 8-K
sec.gov
WHWK
Whitehawk Therapeutics Expands ADC Pipeline with New Option Agreement for Use of CPT113 Linker-Payload
prnewswire.com
WHWK
Whitehawk Therapeutics to Participate in the TD Cowen 7th Annual Oncology Innovation Summit
prnewswire.com
WHWK
Whitehawk Therapeutics to Participate in 2026 Stifel Virtual Targeted Oncology Forum
prnewswire.com
WHWK
Form 8-K
sec.gov
WHWK
Whitehawk Therapeutics Announces $87.5M Private Placement Equity Financing
prnewswire.com
WHWK
Form 8-K
sec.gov
WHWK
Whitehawk Therapeutics Reports First Quarter 2026 Financial Results and Recent Highlights
prnewswire.com
WHWK
Whitehawk Therapeutics Presents Comprehensive Preclinical Data Highlighting its Next-Generation ADC Portfolio at the AACR 2026
prnewswire.com
WHWK